Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index; 81 of the 118 sources its claims cite were checked for support.

The promise and challenge of therapeutic genome editing

Open access
Doudna, Jennifer A. · 2020 · Nature

Abstract

Genome editing, which involves the precise manipulation of cellular DNA sequences to alter cell fates and organism traits, has the potential to both improve our understanding of human genetics and cure genetic disease. Here I discuss the scientific, technical and ethical aspects of using CRISPR (clustered regularly interspaced short palindromic repeats) technology for therapeutic applications in humans, focusing on specific examples that highlight both opportunities and challenges. Genome editing is—or will soon be—in the clinic for several diseases, with more applications under development. The rapid pace of the field demands active efforts to ensure that this breakthrough technology is used responsibly to treat, cure and prevent genetic disease. The scientific, technical and ethical aspects of using CRISPR technology for therapeutic applications in humans are discussed, highlighting both opportunities and challenges of this technology to treat, cure and prevent genetic disease.

Overview

CoChat Summary

TL;DR

This review argues that therapeutic genome editing, especially CRISPR-Cas9, is moving toward the clinic for some monogenic diseases but still faces major delivery, precision, safety, cost, and governance challenges. It contrasts somatic editing with heritable germline editing and calls for responsible, regulated use.

Key findings

  • Monogenic diseases are a major target: ~5,000 are known and affect at least 250 million individuals. Sickle cell disease, caused by a single A-to-T mutation in β-globin, could be treated ex vivo by correcting the mutation in hematopoietic stem/progenitor cells or reactivating γ-globin; ~100,000 US patients and millions more in African and Asian countries are potential candidates.
  • Duchenne muscular dystrophy affects one in 5,000 males at birth and can involve >3,000 mutations, mostly at hotspots; restoring ~15% of normal dystrophin expression may provide clinical benefit. In animal studies, systemic AAV CRISPR delivery restored up to 90% dystrophin in ΔEx50 mice, and in dogs dystrophin levels were restored to 3–90% of normal with improved muscle appearance.
  • Delivery is a central bottleneck: ex vivo editing favors electroporation of Cas9 ribonucleoprotein complexes, while in vivo delivery uses viral vectors such as AAV or lipid nanoparticles. AAV can carry only ~4.7 kb, not much larger than the 4.2 kb SpCas9 gene, so corrective insertion often requires two AAV vectors.
  • Safety and governance concerns include off-target and imprecise editing, rare large deletions and complex rearrangements, possible immunogenicity from pre-existing Cas9 antibodies/T cells, and unresolved long-term safety. For germline editing, the paper states it is inappropriate to perform editing that culminates in human pregnancy at this time, while in vitro embryo/gamete research should be allowed with oversight.

Methods

  • Narrative review by Jennifer A. Doudna; no systematic search strategy, primary dataset, or new experimental results are reported.
  • Synthesizes CRISPR-Cas therapeutic genome editing, including sickle cell disease and DMD examples, delivery modalities, accuracy/safety issues, clinical development, and ethical/regulatory discussion of somatic versus germline editing.
  • Draws on cited animal studies, early clinical trials, and international scientific/organizational positions; no sample size or formal analysis is stated in the paper.

Limitations

  • Stated: delivery remains perhaps the biggest bottleneck to somatic genome editing; AAV has packaging, immunogenicity, and scalable GMP production/cost challenges, while lipid nanoparticles can be toxic and cell-type selective.
  • Stated: off-target and imprecise editing, large deletions, and complex rearrangements occur at low frequency but could be clinically significant; immunogenicity and long-term safety/efficacy of edited cells in vivo remain largely unknown.
  • Stated and evident: germline editing raises unresolved scientific questions about DNA repair in early human embryos and ethical/policy questions; as a review, the paper provides no new primary data and relies on cited studies and early-stage clinical information.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-1978-5

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1
Fig. 1 CC BY · PubMed Central
Fig. 2
Fig. 2 CC BY · PubMed Central
Fig. 3
Fig. 3 CC BY · PubMed Central
Fig. 4
Fig. 4 CC BY · PubMed Central
Fig. 5
Fig. 5 CC BY · PubMed Central

Verification

Claims the paper makes

40 Valid · 10 Not valid · 12 Not checked · 36 Own results and interpretations

45 more claims · 23 with their cited sources checked

Create a free account to see all 98 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 160 references

Cited by

See all 1,130

Metadata

Authors
Doudna, J. A.
Affiliations
QB3 (US)
Corresponding author
Doudna, Jennifer A.
Venue
Nature
Published
2020-02-12
Volume
578
Issue
7794
Pages
229-236
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3006116138
Cited by
1,126
References
160
Citations by year
2026: 123 · 2025: 169 · 2024: 184 · 2023: 259 · 2022: 173 · 2021: 144 · 2020: 73
FWCI
15.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • National Science Foundation (1817593)
  • Howard Hughes Medical Institute
  • W. M. Keck Foundation
  • Innovative Genomics Institute
  • Multiple Sclerosis Society
  • National Institutes of Health
  • Defense Advanced Research Projects Agency (HR0011- 17-2-0043)
  • Advanced Research Projects Agency
  • National Human Genome Research Institute (RM1HG009490)
  • National Institute of Allergy and Infectious Diseases (U01AI142817)
  • Common Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
therapeutic genome editing, CRISPR, genetic disorders, gene therapy, ethics of gene editing, precision genome editing, clinical translation
MeSH terms
Gene Editing, Anemia, Sickle Cell, Humans, Organ Specificity, Genome, Human, Germ-Line Mutation, Muscular Dystrophy, Duchenne, beta-Globins, Patient Safety, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The promise and challenge of therapeutic genome editing. https://app.cochat.ai/papers/10.1038/s41586-020-1978-5
The paper
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature. https://doi.org/10.1038/s41586-020-1978-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.